NCT02756897View on ClinicalTrials.gov

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

July 7, 2016

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic LymphomaSmall Lymphocytic Lymphoma
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT02756897 - Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter